Media ReleasesAuscann Group Holdings

View All Auscann Group Holdings News


AusCann Announces Pharmaceutical Executive Joins Board

Thursday, 27 September 2018 – Leading medical cannabis company AusCann Group Holdings Limited (ASX:AC8) (AusCann or ‘the Company’) is pleased to advise that experienced pharmaceutical executive, Dr Paul MacLeman, has today joined the AusCann Board as an Executive Director.

Dr MacLeman has over 25 years’ board and executive experience across the life sciences, agricultural and not for profit sectors. This includes strategy formulation, capital raising, business development, technology commercialisation and sales & marketing. He has also launched a variety of products in Australia, the US and Asia, founded life sciences start-ups in the biologics area and worked in investment banking.


For further information please download PDF attached:
Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.